Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
Poster to be presented at 38th Annual Meeting of the Society for Immunotherapy of Cancer on November 4, 2023
NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) — Indaptus Therapeutics, Inc. (Nasdaq:INDP) announces it will be presenting interim data from the first cohort of four patients in the Phase 1 INDP-D101 trial of its lead compound, Decoy20. The interim data, released today in abstract form, demonstrated that as of August 31, 2023, each of the first cohort participants experienced transient activation of biomarkers associated with innate and/or adaptive immune responses, and generally expected transient adverse events, both associated with predicted rapid clearance of Decoy20. The data in full will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) on November 4. The conference will be held from November 1-5, 2023 in San Diego.